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Abstract: Fludarabine is an antineoplastic agent used in the treatment of hematological 
malignancies, particularly chronic lymphocytic leukemia (CLL) and indolent B-cell lymphoma. 
Because of its immunosuppressive effects, fludarabine has been added to reduced intensity 
conditioning regimens. The oral formulation of fludarabine has become widely available. 
Pharmacokinetic studies have shown that an oral dose of 40 mg/m2/d would provide systemic 
drug exposure similar to the standard intravenous (IV) dose of 25 mg/m2/d. The oral dose can 
be taken once daily without any dietary restrictions. Dose adjustments are mandatory in patients 
with renal impairment to avoid increased toxicity. Several noncomparative trials in previously 
untreated and treated patients with CLL have shown that treatment with the oral formulation 
demonstrates similar efficacy compared to historical control groups treated with the IV formu-
lation. The tolerability profile of oral fludarabine seems similar to that of the IV formulation. 
Myelosuppression and infectious complications are the most frequently reported adverse events. 
Gastrointestinal toxicity is more frequent with the oral formulation, but is usually of mild or 
moderate severity. Although oral fludarabine makes treatment more convenient, health care 
workers must be aware of the compliance behavior of each patient.
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Introduction
Nucleoside analogues (NA) constitute an important class of antimetabolites used 
in the treatment of hematological malignancies and more recently in solid tumors. 
The NA family includes various pyrimidine and purine analogues (PA). Cytosine 
arabinoside and gemcitabine are well known pyrimidine analogues. The two oldest 
PA are 6-mercaptopurine and 6-thioguanine, available in an oral formulation and used 
especially in the treatment of acute leukemias. The next generation of PAs consist of 
cladribine, pentostatin, and fludarabine. These molecules have been available worldwide 
since the 1990s. Three novel PA, clofarabine, nelarabine, and forodesine, have been 
introduced in clinical trials and are entering daily practice.
For several decades the standard treatment for chronic lymphocytic leukemia (CLL) 
has been single-agent chlorambucil or alkylator-based combination treatments. These 
regimens were very effective in controlling symptoms and tumor burden although 
complete response (CR) rate was low.1
Fludarabine is the PA most extensively studied in the treatment of indolent 
B-cell malignancies. Fludarabine monotherapy has yielded high response rates in 
untreated and treated CLL patients as well.2–4 Later attempts to further improve CR 
and response duration have been explored with the use of fludarabine in combination Drug Design, Development and Therapy 2009:3 242
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with chemotherapeutic agents and/or nonchemotherapeutic 
agents like monoclonal antibodies.
An oral formulation of fludarabine has been developed. 
In 2001, the UK’s National Institute for Clinical Excellence 
(NICE) recommended the use of the oral formulation 
instead of the intravenous (IV) formulation. Since then 
oral fludarabine became available in many areas of Europe 
and Canada. In December 2008, the US Food and Drug 
Administration (FDA) approved oral fludarabine for the 
treatment of relapsed CLL.
Pharmacodynamic properties
Fludarabine or 5’-monophosphate of F-ara-A functions 
as a prodrug. After the dephosphorylation of fludarabine 
to F-ara-A by the 5’-nucleotidase activity on erythrocytes, 
endothelium, and vascular linings of large body organs, 
F-ara-A is taken into cells by nucleoside-specific membrane 
transporters. After entering the cell F-ara-A is rephosphorylated 
to monophosphate by deoxycytidine kinase and subse-
quently to diphosphate and triphosphate. The triphosphate 
F-ara-ATP appears to be the only metabolite with cytotoxic 
activity. The principal mechanism of action of F-ara-ATP is 
inhibition of DNA and RNA synthesis. F-ara-ATP inhibits 
DNA polymerases, DNA primase, DNA ligase, and also 
ribonucleotide reductase. Inhibition of ribonucleotide reduc-
tase lowers the cellular concentration of the normal pool 
of deoxynucleotides, changing the ratio of F-ara-ATP to 
deoxyadenosine 5’-triphosphate (dATP) and promoting the 
incorporation of F-ara-AMP in DNA. Inhibition of the other 
mentioned enzymes makes further DNA extension and liga-
tion to other DNA fragments impossible. F-ara-AMP seems 
also resistant to removal by proofreading activities. This makes 
F-ara-AMP an effective chain terminator leading to inactiva-
tion of DNA synthesis and accumulation of DNA breaks 
followed by initiation of programmed cell death or apoptosis 
(p53-dependent and -independent). Quiescent lymphocytes 
are continually breaking and rejoining their DNA, which 
explains why PA can express cytotoxicity in malignancies 
where proliferation is not impressive. F-ara-ATP seems the 
sole PA capable of inhibiting RNA synthesis.5 Incorporation 
of F-ara-AMP in RNA results in repression of gene transcrip-
tion leading to reduced expression of proteins that may be 
important for cell survival. The lack of survival proteins can 
induce cell death in dividing as well as resting cells.6
Pharmacokinetic properties
Two bioavailability studies of oral fludarabine have been 
reported. The first study tested a liquid formulation consisting of 
the injectable solution and demonstrated a 75% bioavailability.7 
The second study tested tablets with immediate-release 
fludarabine and suggested 55% oral availability that was dose 
independent. The intra-individual variation in bioavailability 
was low although bioavailability ranged from 30% to 80% 
between patients. F-ara-A could be detected in plasma 15 to 
30 minutes after oral dosing with reaching a maximum plasma 
concentration (Cmax) approximately after 1.1–1.2 hours. With 
the 50 mg IV dose, Cmax is reached immediately at the end of 
the infusion and is three times higher than Cmax with the 90 mg 
oral dose. However, oral dose Cmax was similar to the IV dose 
Cmax when measured 30 to 60 minutes after termination of the 
infusion. The linear dose proportional increase in area under 
the plasma concentration-time curve (AUC (0–24 hours)) seen 
with different IV dosages was also noted for the oral adminis-
tration. The AUC (0–24 hours) attained after a 90 mg oral dose 
was similar to that attained after a 50 mg IV dose.8 It has also 
been shown that pharmacokinetics do not significantly differ 
when oral fludarabine is taken with or without food. The time 
to Cmax was slightly extended by the presence of food but the 
terminal half-life was unaffected.9
Elimination of F-ara-A is largely by renal excretion. 
Approximately 37% ± 5% of a 30-minute infusion was 
recovered in the urine within 24 hours, rising to 57% ± 7% 
after 72 hours. Similar F-ara-A elimination kinetics were 
observed after oral administration. There is heterogeneity 
among individuals with respect to the rate of F-ara-ATP 
accumulation and retention leading to a half-life ranging 
from a few hours to a few days. F-ara-ATP is a relatively 
long-lived active metabolite, which makes daily administra-
tion convenient.5 A pharmacokinetic study of oral fludarabine 
in relapsed indolent B-cell non-Hodgkin lymphoma showed 
that time to Cmax, AUC (0–24 hours), elimination time, and 
bioavailabily in Japanese patients were comparable with the 
data obtained in Caucasian patients suggesting no ethnic 
differences.10
All these studies have suggested that a once-daily oral 
dose of 40 mg/m2/d given as immediate-release tablets 
will provide a similar systemic exposure as an IV dose of 
25 mg/m2/d, independently of food intake.11
Therapeutic efficacy
No randomized controlled trials (RCT) have compared the 
efficacy of oral versus IV fludarabine, neither in CLL nor 
in indolent lymphoma. Some observational studies with 
oral fludarabine reporting safety and efficacy were found. 
Some data were retrieved from published full papers, some 
from abstracts. Efficacy and safety data were compared with Drug Design, Development and Therapy 2009:3 243
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historical data concerning treatment with IV fludarabine 
(Table 1).
Single-agent fludarabine  
in previously treated CLL
One of the earliest published single-center noncomparative 
studies reported on the outcome of treatment with single-
agent fludarabine IV in 68 patients with previously treated 
CLL. CR was achieved in 13% and partial response (PR) in 
44% of patients. The authors concluded that fludarabine was 
a new agent with marked activity against CLL and excellent 
tolerance. The response rates were superior to those of other 
single-agents and comparable with the results of combination 
regimens in previously treated patients.2
In a prospective multicenter phase II clinical trial, 
relapsed/refractory CLL patients were treated with oral 
fludarabine 40 mg/m2 for five days every four weeks for 
a total of six to eight cycles. Seventy-eight patients were 
evaluable. Median age was 63.4 years (range 55–72 years). 
Overall response (OR) rate and CR according to National 
Cancer Institute-sponsored Working Group (NCI-WG) 
criteria were 51.3% and 17.9%.12 Grade 3–4 neutropenia 
was seen in 53.8% of patients although grade 3–4 infections 
were reported in only 7.7% of cases. Gastrointestinal toxicity 
was more common than previously reported with the IV 
formulation but was generally mild to moderate. Grade 1–2 
nausea/vomiting was seen in 37% of patients with only 1.3% 
complaining of grade 3 nausea/vomiting. Grade 1–2 diarrhea 
was noticed in 34.6% of patients with grade 3 observed in 
3.8% of patients.13
Single-agent fludarabine in untreated CLL
A meta-analysis selected five CLL RCTs comparing single-
agent PA with alkylator-based regimens as front-line treat-
ment. OR, CR, and progression-free survival (PFS) were in 
favor for the PA although overall survival (OS) was identical. 
Although the incidence of grade 3–4 neutropenia was 
significantly higher in patients treated with PA infections were 
not significantly increased.4 One of these trials compared 
fludarabine IV with chlorambucil. Efficacy and safety data 
for the fludarabine-treated patients were as follows: OR 
63% and CR 20% (NCI-WG criteria), median PFS, and OS 
20 and 66 months, respectively. Grade 3–4 neutropenia was 
seen in 27% of patients, with grade 3–4 infections diagnosed 
in 16% of patients.14
Eighty-one previously untreated CLL patients with a 
median age of 61.2 years (range 30–75 years) were treated 
with oral fludarabine 40 mg/m2/d for five days every 
four weeks for a total of six or eight cycles. OR was 80.2% 
with a CR of 12.3% (NCI-WG criteria). Median time to 
progression was 841 days. Grade 3–4 neutropenia and 
infections were reported in 32.1% and 4.9% of patients, 
respectively. Gastrointestinal toxicity was more common 
with the oral formulation, but was generally mild and did not 
require treatment. Forty-two percent of patients experienced 
any degree of diarrhea with grade 3–4 in 6.2% of patients. 
Any degree of nausea or vomiting was experienced by 38.2% 
of patients, with only 1.2% grade 3–4. This toxicity did not 
cause compliance problems or withdrawal from the study. 
Oral fludarabine did not adversely affect quality of life and 
may even improve emotional and insomnia scores.15
The National Cancer Institute of Canada Clinical Trials 
Group conducted a phase II study evaluating OR to oral 
fludarabine in previously untreated CLL patients. Patients 
were treated with oral fludarabine 40 mg/m2/d for five 
days every 28 days for a maximum of six or eight cycles. 
One hundred twenty-six patients were eligible with a median 
age of 60.9 years. The OR was 64% with CR of 18% 
(NCI-WG criteria). Median PFS at a median follow up of 
23.2 months was 15.3 months. Neutropenia grade 3–4 was 
observed in 51% of patients. The authors concluded that oral 
fludarabine is associated with response rates and a toxicity 
profile comparable to those of IV fludarabine given on a 
similar schedule.16
In 1999, a multicenter RCT (LRF CLL4) comparing 
fludarabine, fludarabine with cyclophosphamide (FC) and 
chlorambucil as front-line treatment in CLL was initiated. 
Fludarabine was given IV till February 2001 when the 
oral formulation became available. One hundred seven of 
196 patients allocated to the fludarabine arm and 116/196 
patients allocated to the FC arm received the oral formula-
tion. Oral fludarabine as single-agent was given at a dose 
of 40 mg/m2/d for five days every 28 days for six cycles. 
The oral FC arm consisted of fludarabine 24 mg/m2/d plus 
cyclophosphamide 150 mg/m2/d each for five days every 
28 days for six cycles. No difference in hematological and 
nonhematological toxicities was seen for oral and IV fluda-
rabine. However responses seemed better for IV compared 
to oral therapy (Fludarabine: CR/Nodular PR [NPR] 54% vs 
41%; FC: CR/NPR 73% vs 59%). The authors of this study 
concluded that the observed difference in response was prob-
able not due to the route of administration of fludarabine, but 
was more likely because of the inclusion of older patients 
with a poorer prognosis later in the study when all patients 
were guaranteed to receive oral therapy. The response rate 
also decreased by year of entry in the chlorambucil arm.17Drug Design, Development and Therapy 2009:3 244
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Table 1 Results of clinical trials with fludarabine as single-agent or in combination given intravenously or orally
References RCT n Median 
age
Route Treatment regimen OR (%) CR (%) PFS (m) Neutropenia (%) 
Grade 3–4
Infections (%) 
Grade 3–4
Single-agent fludarabine in previously treated CLL
Keating2 no 68 60 iv F 25–30 mg/m2 × 5/28d 57 13 16 (OS) 56 (courses) na
Boogaerts13 no 78 63.4 oral F 40 mg/m2 × 5/28d 51,3 17,9 na 53.8 7.7
Single-agent fludarabine in untreated CLL
Leporrier34 yes 341 62 iv F 25 mg/m2 × 5/28d 71,1 40,1 31.7 38 (courses?) na
rai14 yes 179 64 iv F 25 mg/m2 × 5/28d 63 20 20 27 16
eichhorst27 yes 164 59 iv F 25 mg/m2 × 5/28d 83 7 20 26 8.7
Flinn28 yes 137 61 iv F 25 mg/m2 × 5/28d 59 7 19 63 na
Catovsky29 yes 196 64 iv-oral F 25 (40) mg/m2 × 5/28d 80 15 28 na na
rossi15 no 81 61.2 oral F 40 mg/m2 × 5/28d 80,2 12,3 27 32.1 4.9
Shustik16 no 126 60.9 oral F 40 mg/m2 × 5/28d 64 18 15.3 51 na
Fludarabine plus cyclophosphamide in treated CLL
wierda21 no 111 59 iv F 30 mg/m2 × 3/28d + 
C 300 mg/m2 × 3/28d
67 12 36 47 (courses) na
robak22 yes 276 63 iv F 25 mg/m2 × 3/28d +  
C 250 mg/m2 × 3/28d
58 13 20.6 40 19
Forconi32 no 12 65 oral F 25 mg/m2 × 4/28d +  
C 120 mg/m2 × 4/28d
83,5 25 48 (eFS) 25 16.6
Fludarabine plus cyclophosphamide in untreated CLL
eichhorst27 yes 164 58 iv F 25 mg/m2 × 3/28d +  
C 250 mg/m2 × 3/28d
94 24 48 55.5 8.7
Flinn28 yes 141 61 iv F 20 mg/m2 × 5/28d +  
C 600 mg/m2/28d
74 23 32 69 na
Catovsky29 yes 196 65 iv-oral F 25(24) mg/m2  
× 3(5)/28d + C 250  
(120) mg/m2 × 3(5)/28d
95 38 43 na na
Hallek30 yes 409 61 iv F 25 mg/m2 × 3/28d +  
C 250 mg/m2 × 3/28d
95 27 32 20,9 14.8
Cazin31 no 75 57 oral F 30 mg/m2 × 5/28d +  
C 200 mg/m2 × 5/28d
80 53 60 52 16
Forconi32 no 14 65 oral F 25 mg/m2 × 4/28d +  
C 120 mg/m2 × 4/28d
100 61.5 48 (eFS) 21 0
Laurenti33 no 35 68 oral F 30 mg/m2 × 3/28d +  
C 250 mg/m2 × 3/28d
77 40 23 45.7 0
Fludarabine plus alemtuzumab in treated CLL
elter23 no 36 61.4 iv F 30 mg/m2 × 3/28d +  
A 30 mg × 3/28d
83 30 35.6 (OS) 26 (courses) 5 (courses)
Hwang24 no 5 72 oral-sc F 40 mg/m2 × 5/28d +  
A 30 mg/d1–3–5/28d
100 60 na na na
Fludarabine-cyclophosphamide plus alemtuzumab in treated CLL
elter25 no 55 63 iv-sc F 25 mg/m2 × 3 +  
C 200 mg/m2 × 3 +  
A 30 mg × 3/28d
83 38 na na na
Montillo26 no 25 57 oral-sc F 40 mg/m2 × 3 +  
C 250 mg/m2 × 3 +  
A10–20 mg × 3/28d
79 37 na 43 (courses) na
Abbreviations: C, cyclophosphamide; CR, complete response; EFS, event free survival; F, fludarabine; Infections (%), % of patients treated; n, number of evaluable patients; na, not avail-
able; Neutropenia (%), % of patients treated; OR, overall response; OS, overall survival; PFS(m), progression free survival (months); RCT, randomized control trial; sc, subcutaneous.Drug Design, Development and Therapy 2009:3 245
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Fludarabine combination therapy
A variety of agents has been combined with fludarabine 
in an attempt to improve efficacy. Prednisone or chloram-
bucil in addition to fludarabine increased hematological 
toxicity and the incidence of infection without improving 
response rates.14,18 In vitro and in vivo data have shown 
synergy between fludarabine and DNA-damaging agents 
(cyclophosphamide, mitoxantrone, cisplatinum, etc). DNA 
interstrand cross-links induced by cyclophosphamide can 
persist because DNA repair enzymes are inhibited by 
fludarabine. Cyclophosphamide also enhances the incorpora-
tion of F-ara-AMP in DNA, enhancing cell death.19 Synergy 
between fludarabine and monoclonal antibodies (rituximab, 
alemtuzumab) has also been shown. Rituximab downregu-
lates antiapoptotic proteins while fludarabine downregulates 
anticomplement proteins, making cells more vulnerable to 
apoptosis.20 The most thoroughly studied combinations are 
FC and FC plus rituximab (FCR) IV . Other effective combina-
tions are FC or FCR plus mitoxantrone (FCM, FCM-R) and F, 
FC or FCR plus alemtuzumab (F-Cam, FC-Cam, CFAR).
Fludarabine combination in previously 
treated patients
One hundred eleven CLL patients with recurrent/refractory 
disease were treated at a single center with fludarabine 
30 mg/m2 and cyclophosphamide 300 mg/m2 IV for three 
days, every four weeks for a total of six planned cycles. 
Median age was 59 years (range 31–79 years). OR was 67% 
with a CR of 12% (NCI-WG criteria). The estimated time to 
disease progression for responders was 36 months. Median 
OS for all patients was 31 months and exceeded 71 months 
for the complete responders. Grade 3–4 neutropenia was 
observed in 47% of treatment cycles.21
The rituximab in the study of relapsed chronic lymphocytic 
leukemia (REACH) trial compared FC with FCR IV in 
previously treated CLL patients. 552 patients with a median 
age of 63 years were randomized. OR (70% vs 58%) and 
CR (24% vs 13%) (NCI-WG criteria) was better for FCR. 
Median PFS improved from 20.6 to 30.6 months. Grade 3–4 
neutropenia was comparable (42% vs 40%) as was infection 
rate (18% vs 19%).22
A phase II study determined the efficacy and safety 
of fludarabine 30 mg/m2 and alemtuzumab 30 mg IV 
administered on three consecutive days, every 28 days for 
up to six cycles in CLL patients with relapsing/refractory 
disease. Thirty-six patients with a median age of 61.4 years 
(range 38–80 years) were treated. OR reached 83% with 30% 
CR (NCI-WG criteria). Grade 3–4 neutropenia and infections 
were seen in 26% and 5% of treatment cycles. Median OS 
was 35.6 months.23
A pilot study assessed the safety and efficacy of oral 
fludarabine 40 mg/m2 for five days and subcutaneous (sc) 
alemtuzumab 30 mg on days 1, 3, and 5 every four weeks 
for a total of two to six cycles in the treatment of five 
relapsed/refractory CLL patients. Median patient age was 
72 years (range 60–81 years). All patients responded (CR, 3; 
PR, 2). The authors concluded that this regimen constituted a 
well-tolerated, self-administered, outpatient-based treatment 
in elderly patients.24
The combination of fludarabine (25 mg/m2 IV), 
cyclophosphamide (200 mg/m2 IV) and alemtuzumab 
(30 mg sc) was tested in a phase II trial. Fifty-five patients with 
relapsing/refractory CLL were included. Twenty-four patients 
were evaluable for response and safety. Median age was 63 years 
(range 47–78 years). OR was 83% with CR of 38%.25
Another phase II trial enrolled 25 patients with relapsing/
refractory CLL. The treatment regimen consisted of fluda-
rabine 40 mg/m2 and cyclophosphamide 250 mg/m2 given 
orally for three days and alemtuzumab 10 to 20 mg given 
sc for three days. Cycles were repeated every 28 days for a 
maximum of six cycles. Median age was 57 years (range 
42–79 years). Grade 3–4 neutropenia was seen in 43% of 
administered courses. Four major infections were mentioned. 
OR was 79% with CR 37%.26
Fludarabine combination  
in untreated patients
Three RCTs compared fludarabine with FC in untreated CLL 
patients. FC chemotherapy resulted in a higher CR and OR 
(23.4% to 38% and 74.3% to 95%, respectively) compared 
with fludarabine alone (4.6% to 15% and 59.5% to 83%, 
respectively). FC also resulted in a longer PFS. So far, no 
difference in OS has been seen. Grade 3–4 neutropenia was 
increased although the rate of severe infections was compa-
rable in both study arms of all three studies.27–29
The German CLL study group (GCLLSG) CLL8 trial 
compared FC versus FCR IV as front-line treatment in CLL. 
Eight hundred seventeen patients with a cumulative illness 
rating scale (CIRS) score of up to 6 and a creatinine clear-
ance (CrCl)  70 ml/min were randomized. The median age 
was 61 years (range 30–81 years). The addition of rituximab 
almost doubled the CR rate from 27% to 52% and improved 
OR to 95%. Median PFS was 42.8 months for the FCR group 
versus 32 months for the FC group. Grade 3–4 neutropenia 
increased from 20.9% to 33.6%. Grade 3–4 infection rate 
remained comparable (14.8% versus 18.8%).30Drug Design, Development and Therapy 2009:3 246
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A multicenter single-arm study tested the efficacy and 
toxicity of the oral combination of fludarabine (30 mg/m2) 
and cyclophosphamide (200 mg/m2) for five days every 
28 days for six cycles in 75 untreated CLL patients. The 
median age of the patients at the time of inclusion was 
57 years (37–66 years). Oral FC demonstrated high efficacy 
with OR and CR of 80% and 53%, respectively. Median OS 
and median treatment free interval had not been reached after 
seven years of follow-up. Median PFS was five years. Toxic-
ity was acceptable with grade 3–4 neutropenia and infections 
seen in 52% and 16% of treatment cycles. Gastrointestinal 
toxicity was generally limited to grade 1–2. Nausea grade 
3–4 was mentioned in 2% of treatment cycles while vomiting 
and diarrhea grade 3–4 was mentioned in 0.27% and 0.2% 
of cycles, respectively. Antiemetic prophylaxis was recom-
mended to avoid lesser drug absorption due to vomiting. The 
authors concluded that compliance to the oral formulation 
was excellent.31
Efficacy and toxicity of oral FC at reduced doses 
(fludarabine 25 mg/m2 (max 40 mg/d) d1–4 and cyclophos-
phamide 120 mg/m2 (max 200 mg/d) d1–4 every four weeks 
for a maximum of four cycles) in elderly patients (65 years) 
with CLL was tested. OR in the 14 previously untreated 
patients was 100% with a CR of 61.5% and event-free 
survival (EFS) at 24 months of 71%. In the 12 previously 
treated patients an OR of 83.5% with CR of 25% was seen 
with an EFS at 24 months of 83%. No patients reported 
nausea, vomiting, or required antiemetic treatment. Grade 2 
diarrhea was reported in two patients.32
Thirty-seven patients with previously untreated CLL 
received oral fludarabine (30 mg/m2) and cyclophosphamide 
(250 mg/m2) d1–3 every four weeks for six cycles. Among 
the 35 evaluable patients, OR was 77% with CR of 40%. The 
median PFS was 23 months and median time to retreatment 
was 38 months. Grade 3–4 neutropenia was observed in 
16 patients. Gastrointestinal toxicity was mild. Nausea grade 
1–2 was seen in 12 patients and grade 3 in two patients. 
Vomiting grade 1–2 was seen in six patients with one patient 
reporting grade 3 toxicity.33
Tolerability
Hematological toxicity
Fludarabine suppresses severely bone marrow function with 
induction of neutropenia, thrombocytopenia and anemia. 
Myelosuppression is the major dose-limiting adverse effect. 
In a RCT conducted by the French Cooperative Group on 
CLL fludarabine IV induces grade 3–4 neutropenia, thrombo-
cytopenia, and anemia in 38%, 15%, and 18% of previously 
untreated CLL patients, respectively.34 This myelotoxicity 
is even more pronounced when patients with recurrent of 
refractory disease are treated with fludarabine. Neutropenia 
and thrombocytopenia were observed in 56% and 25% of 
evaluable courses, respectively.2 Using the oral formulation, 
grade 3–4 neutropenia, thrombocytopenia, and anemia devel-
oped in 32.1%, 4.9%, and 9.9% of previously untreated and 
53.8%, 25.6%, and 4.4% of previously treated CLL patients, 
respectively.13,15 Data from two RCT’s combining FC with or 
without rituximab were recently presented. With front-line 
treatment grade 3–4 neutropenia, thrombocytopenia and 
anemia were observed in 21%, 11%, and 7% of the FC group 
and in 34%, 7%, and 5% of the FCR group, respectively.30 
In patients previously treated, grade 3–4 neutropenia, throm-
bocytopenia, and anemia were seen in 40%, 9%, and 5% of 
patients treated with FC and in 42%, 11%, and 2% of patients 
treated with FCR, respectively.22 Prolonged cytopenia after 
fludarabine-based combination regimens have been observed. 
It can take several months before resolution is complete 
although recurrent cytopenic episodes can occur in the first 
year of remission.35,36 Fludarabine given as first line or salvage 
treatment frequently reduces CD4 and CD8 cells to less than 
200/µl during the treatment period and this suppression can 
persist for more than one year.18,37
infectious complications
Infection in CLL is multifactorial. The major risk factors 
are immune defects inherent to the primary disease process 
and therapy related immunosuppression. Fludarabine is not 
only linked to a higher risk of infections than alkylating-
agent-based treatment, it changes also the spectrum of 
infections seen in these patients. In addition to bacterial 
infections common to patients with CLL, opportunistic infec-
tions (Listeria, mycobacterial species, Nocardia, Candida, 
Aspergillus, Cryptococcus, Pneumocystis, and herpesviruses) 
become more frequent. Although the value of routine antiviral 
and pneumocystis prophylaxis in fludarabine treated patients 
is not examined prospectively, a lot of clinicians recommend 
routine antibacterial and antiviral prophylaxis during and 
after PA treatment.38 Myeloid growth factor support can be 
used according to American Society of Clinical Oncology 
guidelines to reduce myelosuppression as well to allow the 
delivery of full-dose therapy.39 Recently, when reviewing 
the data of the GCLLSG CLL4 trial, it was suggested that 
routine antibiotic or virostatic prophylaxis and pre-emptive 
treatment with G-CSF is not necessary in first-line therapy 
with fludarabine-based regimens in CLL patients younger 
than 66 years.40Drug Design, Development and Therapy 2009:3 247
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Guidelines for the use of intravenous immunoglobulin 
(IVIG) replacement in CLL do not exist. Most clinicians find 
it justifiable to use IVIG in CLL patients with hypogamma-
globulinemia and recurrent bacterial infections.41
CLL patients are not only at risk for acquiring infec-
tions but are also at risk for reactivation of latent infections 
(herpesviruses, Toxoplasma, Hepatitis B virus, JC virus).42,43 
Progressive multifocal leukoencephalopathy (PML) is a 
subacute demyelinating disease caused by infection of 
oligodendrocytes with the JC virus. This neurological 
disorder is well known in AIDS patients but is diagnosed 
more frequently also among patients with hematological 
malignancies, chronic inflammatory diseases and after organ 
transplantantion due to the use of immunosuppressive agents. 
Recently there were concerns about the potential for PML 
among rituximab-treated patients. However, 26/52 reported 
cases were also treated with PA in the past.44 One case of 
PML developing in a CLL patient after treatment with oral 
fludarabine has been published. This patient developed 
symptoms seven months after completion of treatment when 
T-lymphocytes were still very low.45
The combination of fludarabine plus corticosteroids and 
also fludarabine plus chlorambucil must be discouraged 
because the combination significantly increased the severity 
and incidence of infections compared with fludarabine 
monotherapy.46,47
Neurotoxicity
Dose dependent neurotoxicity has been observed with 
fludarabine. The high doses of fludarabine (96 mg/m2/d 
for 5–7 days) used in the treatment of acute leukemia were 
associated with severe late onset neurotoxicity in 36% of 
cases. The clinical symptoms consisted of altered mental 
status, seizures, paraparesis, progressive encephalopathy 
and coma.48 Ocular toxicity, although infrequent, may 
be rapidly sight-threatening and largely irreversible.49 
With conventional dose fludarabine neurotoxicity is 
mild and reversible in the majority of cases. In review-
ing 2,136 patients treated with fludarabine for hemato-
logical malignancies, 336 patients (16%) reported some 
degree of neurotoxicity. Reversible neurological events 
included seizures, loss of consciousness, blurred vision, 
and leg weakness.50 Grade 3 ocular toxicity (subtotal loss 
of vision) and grade 4 (blindness) was reported in 1% 
and 0.3% of patients followed by the group C protocol 
mechanism of the national cancer institute.51 PML must 
be excluded when neurological symptoms occur. As there 
is no known prophylaxis or treatment for neurotoxicity 
except discontinuing fludarabine immediately, a heightened 
awareness of the neurological vulnerability of some patients 
to standard doses of fludarabine is necessitated with the 
increasing use of this PA. In the pivotal trial conducted 
with oral fludarabine, one patient had a severe impairment 
of consciousness during the last treatment cycle. Mild 
consciousness-related adverse events were experienced by 
15.4% of the other patients and 6.4% experienced mild to 
moderate peripheral neuropathy.13
Autoimmune complications
Autoimmune phenomena like autoimmune hemolytic anemia 
(AIHA), autoimmune thrombocytopenia, thrombocytopenic 
purpura, pemphigus, acquired hemophilia, and Evans’ 
syndrome have all been described in CLL. AIHA is the most 
common autoimmune disorder. An incidence of AIHA of 
8.6% in untreated patients and 11% after treatment (mainly 
with alkylating agents) was seen in the MRC CLL trials in 
the last 20 years.52 In the front-line LRF CLL4 trial, AIHA 
was diagnosed equally in the chlorambucil and fludara-
bine patient groups (12%–11%) and was less common in 
patients treated with FC in combination (5%) suggesting a 
preventive effect.29 In the context of heavily pretreated CLL, 
fludarabine is thought to predispose to AIHA. However, in 
the context of previously untreated CLL, fludarabine seems 
no more hemolytic than other agents. AIHA can occur in 
patients with or without a previous history of AIHA, with or 
without a Coombs-positive result and whether in remission 
from their CLL or not. Hemolysis after fludarabine could 
be life threatening and some fatalities have been reported. 
Rechallenge with fludarabine after AIHA should be avoided 
because the majority of patients will develop a recurrence 
of hemolysis.
Gastrointestinal toxicity
In a RCT comparing fludarabine IV and cyclophosphamide, 
doxorubicin and prednisone grade 1–2 nausea/vomiting 
and diarrhea was reported respectively in 5% and 4% of 
patients treated with fludarabine.3 With the oral formula-
tion, grade 1–2 nausea/vomiting was reported in 37% to 
38.2% with grade 3–4 toxicity noticed in 1.2% to 1.3% 
of patients. Grade 1–2 diarrhea was reported in 34.6% to 
42% of patients with 3.8% to 6.2% suffering from grade 
3–4 toxicity.13,15 Gastrointestinal toxicity is of particular 
importance in the assessment of any oral formulation since 
nausea, vomiting, and diarrhea make the drug not only 
unacceptable for the patient but also affect the absorption 
of the drug.Drug Design, Development and Therapy 2009:3 248
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Second malignancies
Prolonged immunosuppression may increase the risk of 
second malignancies. A retrospective analysis has been done 
in 724 CLL patients treated with fludarabine. No increased 
risk was found for second neoplasms already associated with 
a diagnosis of CLL.53
Myelodysplasia and secondary acute myeloid leukemia 
are rarely reported in CLL patients treated with fludarabine 
monotherapy. However the combination of fludarabine with 
DNA-damaging agents may increase this risk up to 10%.54 
Transformation of CLL to large cell lymphoma or Hodgkin’s 
disease is known as Richter’s syndrome (RS). According 
to the literature, 1% to 10% of CLL patients develop this 
high-grade malignancy. The relationship between the 
immunosuppressive effect of PA and monoclonal antibodies 
in the development of this large cell transformation remains 
a controversial issue. In reviewing the literature we were 
not able to show a statistically significant difference in RS 
incidence between patients treated with and without PA. We 
suppose that the profound and early occurring T cell depletion 
could be responsible for RS soon after the start of and 
during treatment whereas the prolonged immunosuppression 
can explain RS later on even when complete remission 
is sustained.55 Some of these lymphoproliferations were 
clearly Epstein–Barr virus (EBV)-mediated.56 Recently it 
was suggested that aggressive lymphomas developing after 
T-cell-depleting therapies should be seen as a novel type of 
immunodeficiency-related lymphoma and not as RS.57
Tumor lysis syndrome
Tumor lysis syndrome (TLS) is a rare complication 
of fludarabine treatment. Clinical and laboratory fea-
tures consistent with TLS were present in only 20 of 
6,137 patients treated with fludarabine (0.33%). After 
intravenous infusion TLS developed approximately on 
day 7. Patients with a high tumor burden, high rate of pro-
liferation, and disease highly responsive to therapy are at 
risk for TLS.58 TLS can be easily prevented with allopurinol 
prophylaxis and the encouragement of hydration with oral 
fluids during treatment.59 Two case reports describing TLS 
after oral fludarabine were published.60,61 One of these 
patients developed TLS during the two first treatment cycles. 
TLS was diagnosed two weeks after the oral administration, 
later than what is seen after IV fludarabine.61
Transfusion and vaccination policy
A small number of transfusion-associated graft-versus-host 
disease was noted after fludarabine treatment. This led to 
the recommendation that fludarabine-treated patients should 
receive irradiated blood products if they require transfusion.62 
There is no international guideline about the duration of this 
recommendation. A lot of clinicians maintain this precau-
tion for at least a year but additional research is required 
to determine whether such a transfusion policy is required 
during the patient’s whole lifetime.
It has been shown that immune responses to vaccination 
in CLL patients are suboptimal due to impaired antibody 
production as well as to defects in antigen presentation.41 
Immunocompetence is further altered by chemotherapy 
through depletion of B- and T-lymphocytes, plasma cells, 
and natural killer cells. Vaccine recommendations specific 
for CLL patients are lacking. However pneumococcal and 
influenza vaccines are advocated for adult patients with 
altered immunocompetence on the basis of proven effective-
ness and an increased risk for infections if these vaccines 
are withheld. Vaccination or revaccination with inactivated 
vaccines should be administered at least three months after 
the end of immunosuppressive treatment if immunocompe-
tence is restored.63 Evaluation of immune recovery should 
not only include measurement of lymphocyte subsets and 
immunoglobulin levels, but also T-lymphocyte proliferation 
in response to specific or nonspecific stimuli.64 Until specific 
scientific data about vaccination in CLL after fludarabine-
based treatment become available and also knowing that 
immune reconstitution after these regimens is slow, it is safe 
to use the guidelines for revaccination of recipients of hema-
topoietic stem cell transplant. This means that inactivated 
influenza vaccine can be administered at least six months 
after the end of a PA-based regimen, while all other inacti-
vated vaccines should begin 12 months after completion of 
these treatments. Vaccination with live vaccines should be 
avoided during treatment with fludarabine and 24 months 
after treatment.63
Dosage and administration  
and dose adjustment
For the treatment of CLL the recommended IV dose of 
fludarabine as a single-agent is 25 mg/m2 daily for five days 
and repeated at 28-day intervals, administered as a 30-minute 
intravenous infusion or as an intravenous bolus injection. 
Oral fludarabine is given at a dosage of 40 mg/m2 once 
daily for five days, repeated every four weeks for up to six 
cycles. The IV combination tested most extensively in phase 
III trials is fludarabine 25 mg/m2 and cyclophosphamide 
250 mg/m2 daily for three days repeated every 28 days for 
six cycles. This is comparable to an oral combination of Drug Design, Development and Therapy 2009:3 249
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fludarabine 40 mg/m2 and cyclophosphamide 250 mg/m2 
daily for three days or fludarabine 24 mg/m2 and cyclophos-
phamide 150 mg/m2 daily for five days repeated every 28 days 
for six cycles. The fludarabine tablets can be taken either on 
an empty stomach or with food, and must be swallowed whole 
with water. They should not be chewed upon or crushed. One 
film-coated tablet contains 10 mg fludarabine. The tablets 
must be stored between 15 °C and 30 °C.
Fludarabine is eliminated primarily through renal 
excretion. Until recently the product monograph of 
fludarabine recommended a dosage reduction of up to 50% 
for patients with a CrCl of 30 to 70 ml/min. Fludarabine 
was even contraindicated in patients with a CrCl  30 
ml/min.65 With the FDA approval of oral fludarabine at the 
end of 2008, a revised product monograph was released 
recommending the following dose adjustments: reduce dose 
by 20% in patients with mild to moderate renal impairment 
(CrCl 30–70 ml/min/1.73 m2) and by 50% in patients with 
severe renal impairment (CrCl  30 ml/min/1.73 m2).66 
Already in previous years these dose adjustments had been 
shown to result in similar drug AUC (0–24 hours) compared 
to patients with normal renal function receiving the standard 
recommended dose.67 Careful monitoring of elderly patients 
(75 years) receiving fludarabine is recommended because 
data in this age group are limited.
Warnings and precautions
Myelosuppression is the major adverse event seen with 
fludarabine treatment. Careful hematologic monitoring is 
required.
Patients treated with fludarabine appear to be at an 
increased risk of infections, particularly opportunistic ones. 
The need for prophylactic antibiotic and virostatic treatment 
must be judged individually.
Fludarabine is relatively contraindicated in patients 
with active autoimmune hemolysis. Monitoring for hemo-
lysis during treatment with fludarabine is warranted. 
Rechallenge with PA after fludarabine-related AIHA should 
be avoided.
Fludarabine must be discontinued immediately when 
neurological symptoms appear.
TLS must be prevented with allopurinol prophylaxis and 
the encouragement of oral hydration especially in patients 
with a high tumor burden.
Fludarabine-treated patients should receive irradiated 
blood products for at least one year and avoid vaccination 
with live vaccines for at least two years after the end of 
treatment.
CrCl should be measured at the start of every treatment 
cycle. Dose adjustments must be made according to the grade 
of reduced renal function.
It is recommended that men and women of childbearing 
potential take contraceptive measures during and for at least 
six months after the cessation of fludarabine because possible 
adverse effects on human fertility have not been adequately 
evaluated.
Convenience and compliance
In September 2001, NICE recommended oral fludarabine in 
preference to the intravenous formulation. The benefits of oral 
fludarabine include ease of administration with no need for 
repetitive venous punctures or indwelling catheters, absence 
of infusion-related adverse events such as extravasation, 
thrombosis, and catheter-related infections, reduced need 
for transportation and travel stress, which could improve the 
quality of life of patients. In addition medical costs should 
be reduced because of fewer hospital visits and fewer health 
care worker interventions.68
Although the use of oral fludarabine seems more 
convenient than the IV formulation, we must be aware of the 
compliance behavior. A patient is optimally adherent if no 
doses are missed, no extra doses are taken, and no doses are 
taken in the wrong quantity or at the wrong time. A patient 
has an optimal persistence if he or she takes a medication as 
long as it is prescribed. Adherence should never be assumed 
even in the treatment of hematologic malignancies. Patients 
must be aware that suboptimal adherence may prove to be the 
greatest barrier to the effective use of oral agents.69
Approximately two thirds of patients with CLL or indolent 
B-cell lymphoma are aged over 60 years. Especially in this 
elderly population the following factors must be taken into 
consideration when prescribing oral chemotherapy: age 
related physiological changes affecting clinical pharmacology 
(decreased absorption, altered distribution and metabolism, 
reduced renal clearance), polypharmacy, the patient’s capacity 
to self-administer medication and safety concerns for the 
older patient and his or her carers.68
Conclusion
CLL combination treatment based on PAs such as fludarabine 
is associated with higher response rates and much longer 
remissions than traditional therapies such as chlorambucil. 
Patients treated with current therapies also seem to have a 
better OS compared to those in historical series. Neverthe-
less, until now no RCT has been able to show a survival 
benefit.Drug Design, Development and Therapy 2009:3 250
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Fludarabine is the only PA with an available oral 
formulation. No RCT is available to formally prove nonin-
feriority of oral to IV fludarabine. The efficacy data retrieved 
from observational studies with oral fludarabine as single-
agent or in combination with cyclophosphamide seem very 
similar to the historical data concerning treatment with IV 
fludarabine. Myelosuppression and infectious complications 
remain the most common adverse events and seem to be inde-
pendent of the administration route. Gastrointestinal adverse 
effects however seem to occur more commonly with the oral 
formulation than previously reported with the IV formulation. 
Nevertheless most adverse events were mild to moderate in 
severity with no drug withdrawals reported.
Oral fludarabine eliminates the need for repetitive 
venous access and its potential complications and reduces 
the visits to the outpatient clinic which means less need for 
transportation and less travel stress. Medical costs should 
be reduced because of fewer hospital visits and fewer health 
care worker interventions. However, in some countries the 
cost of oral anti-cancer agents is much higher than for the 
parenteral counterpart due to reimbursement issues, making 
the oral treatment less appealing.
Treatment adherence is probably not a major issue 
because oral fludarabine is given only three to four days a 
month and can be taken once daily without diet restrictions. 
Compliance can further be improved by optimizing com-
munication between the patient and health care workers 
with adequate education about the treatment schedule and 
possible adverse events.
Oral anticancer drugs are believed to suit elderly patients 
especially. According to data from the Surveillance, Epide-
miology and End Results (SEER) Program of the United 
States National Cancer Institute, 31% of CLL patients are 
aged between 65 and 74 years while 44% are 75 years or 
older. The LRF CLL4 trial has shown that more elderly 
patients were included if oral therapy could be guaranteed. 
Especially in this elderly population we must consider age-
related physiological changes, comorbidities, and polyphar-
macy that can influence the pharmacological properties of 
the oral drug.
Now that oral fludarabine is available in a large part of the 
world and more trials have confirmed efficacy and tolerability 
of the oral formulation, we believe that the IV formulation 
can be replaced by the oral drug when this is more convenient 
for the patient.
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